ArticleAntimicrobial agents and chemotherapy2000
Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Powerful bactericidal activity of moxifloxacin in human leprosy.Antimicrobial agents and chemotherapy · 2008Trial
- Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.PLoS neglected tropical diseases · 2020Article
- An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.BMC infectious diseases · 2018Article
- Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study.Molecular biology research communications · 2017Article
- Nitazoxanide is active against Mycobacterium leprae.PloS one · 2017Article
- DC-159a Shows Inhibitory Activity against DNA Gyrases of Mycobacterium leprae.PLoS neglected tropical diseases · 2016Article
- Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.Risk management and healthcare policy · 2016Review
- Resistance of M. leprae to quinolones: a question of relativity?PLoS neglected tropical diseases · 2013Article
- Leprosy therapy, past and present: can we hope to eliminate it?Indian journal of dermatology · 2010Article
- Are variable-number tandem repeats appropriate for genotyping Mycobacterium leprae?Journal of clinical microbiology · 2008Article
- Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.Antimicrobial agents and chemotherapy · 2007Article
- In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.Antimicrobial agents and chemotherapy · 2006Article
- Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.Antimicrobial agents and chemotherapy · 2006Article
- Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP). Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10 mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slightly more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.